Information for patients and healthcare providers
Visit these websites to learn more about our approved product, and for information about our educational and financial support programs for qualified patients.
View full Prescribing Information and Medication Guide
Open PDFUrovant offers resources for information, advocacy, and support.
Learn moreSafety and reporting adverse events
At Urovant Sciences, we are committed to high standards of product safety, efficacy, and regulatory compliance, including adherence to post-market requirements for reporting adverse events, product complaints, and other reportable events.
Urovant Sciences’ Pharmacovigilance and Product Complaint policy establishes that all employees and agents are part of the Pharmacovigilance System (PV System) and that the PV System performance depends on all stakeholders being aware of and contributing to its activities.
Pharmacovigilance is a companywide, global concept, spanning the whole lifecycle of a product. Although some functions will be more involved than others, every individual in the organization is required to learn about and understand pharmacovigilance-relevant information relating to the products for which the company holds a marketing authorization.
For medical inquiries: medinfo@urovant.com
Patent notices
Please see the following list for US patents covering Urovant Sciences’ products. The absence of a product name from this list, or the absence of a US patent number as associated with any listed product, does not constitute a waiver of Urovant Sciences’ patent rights, or any other intellectual property rights, concerning that product.
GEMTESA® (vibegron)
US 8,247,415
US 8,653,260